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Summary
Background Many countries are exploring the potential of telehealth interventions to manage the rising number of 
people with chronic disorders. However, evidence of the eﬀ ectiveness of telehealth is ambiguous. Based on an 
evidence-based conceptual framework, we developed an integrated telehealth service (the Healthlines Service) for 
chronic disorders and assessed its eﬀ ectiveness in patients with depression. We aimed to compare the Healthlines 
Depression Service plus usual care with usual care alone.
Methods This study was a pragmatic, multicentre, randomised controlled trial with participants recruited from 
43 general practices in three areas of England. To be eligible, participants needed to have access to the internet and 
email, a Patient Health Questionnaire 9 (PHQ-9) score of at least 10, and a conﬁ rmed diagnosis of depression. 
Participants were individually assigned (1:1) to either the Healthlines Depression Service plus usual care or usual care 
alone. Random assignment was done by use of a web-based automated randomisation system, stratiﬁ ed by site and 
minimised by practice and PHQ-9 score. Participants were aware of their allocation, but outcomes were analysed 
masked. The Healthlines Service consisted of regular telephone calls from non-clinical, trained health advisers who 
followed standardised scripts generated by interactive software. After an initial assessment and goal-setting telephone 
call, the advisers called each participant on six occasions over 4 months, and then made up to three more calls at 
intervals of roughly 2 months to provide reinforcement and to detect relapse. Advisers supported participants in the 
use of online resources (including computerised cognitive behavioural therapy) and sought to encourage healthier 
lifestyles, optimise medication, and improve treatment adherence. The primary outcome was the proportion of 
participants responding to the intervention (deﬁ ned as PHQ-9 <10 and reduction in PHQ-9 of ≥5 points) at 4 months 
after randomisation. The primary analysis was based on the intention-to-treat principle without imputation and all 
serious adverse events were investigated. This trial is registered with Current Controlled Trials, number 
ISRCTN 14172341.
Findings Between July 24, 2012, and July 31, 2013, we recruited 609 participants, randomly assigning 307 to the 
Healthlines Service plus usual care and 302 to usual care. Primary outcome data were available for 525 (86%) 
participants. At 4 months, 68 (27%) of 255 individuals in the intervention group had a treatment response compared 
with 50 (19%) of 270 individuals in the usual care group (adjusted odds ratio 1·7, 95% CI 1·1–2·5, p=0·019). Compared 
with usual care alone, intervention participants reported improvements in anxiety, better access to support and advice, 
greater satisfaction with the support they received, and improvements in self-management and health literacy. 
During the trial, 70 adverse events were reported by participants, one of which was related to the intervention 
(increased anxiety from discussing depression) and was not serious.
Interpretation This telehealth service based on non-clinically trained health advisers supporting patients in use of 
internet resources was both acceptable and eﬀ ective compared with usual care. Our results provide support for the 
development and assessment of similar interventions in other chronic disorders to expand care provision.
Funding National Institute for Health Research (NIHR).
Copyright © Salisbury et al. Open Access article distributed under the terms of CC BY.
Introduction
The growing prevalence of chronic disorders is a challenge 
to the capacity of health-care systems, which are mainly 
based on face-to-face consultations between patients and 
doctors. There is international interest in the potential of 
technology to enable individuals to manage their own 
health problems, reducing the need to make appointments 
with health professionals. These technologies, broadly 
termed telehealth, include telephone support, messaging, 
internet-based approaches, and remote monitoring. 
Some interventions can be auto mated and supported by 
non-clinically trained staﬀ , which could expand provision 
and increase access to care. UK health policy envisages 
telehealth becoming mainstream.1 In the USA, the 
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Veterans Health Administration has enrolled more than 
50 000 patients in a home telehealth programme, and 
the Renewing Health Consortium is testing telehealth 
programmes in nine European countries.
Despite this enthusiasm for telehealth, evidence of 
beneﬁ t is ambiguous and inconsistent, in part due 
to insuﬃ  cient theoretical underpinning for many 
interventions.2,3 Systematic reviews in diﬀ erent 
disorders have shown beneﬁ ts from speciﬁ c tech-
nologies in selected patients, but few studies have 
investigated their eﬀ ectiveness in large-scale, real-world 
implementation.2 Furthermore, the focus on speciﬁ c 
applications is of limited value because their use cannot 
be considered in isolation from the health-care system. 
Technology-based solutions have frequently been 
introduced without incorporation into existing models 
of service provision. The NHS Five Year Forward View 
proposes that what is needed is so-called combinatorial 
innovation—an approach that combines diﬀ erent 
technologies and changed ways of working to transform 
care delivery.4
We developed a new model of care to improve 
management of people with chronic disease based on 
making the best use of various technologies in 
combination, supported by non-clinically trained staﬀ  
and integrated with the health-care system. This 
approach incorporates recognised strategies to improve 
management for chronic disease, use of technology to 
implement those strategies in ways that reduce the 
need for face-to-face contact with clinicians, use of 
speciﬁ c telehealth tools which have the best evidence 
of eﬀ ectiveness, and use of technology to ensure 
integration with primary care. The aim is to improve 
access to care, expand care provision without relying on 
clinical staﬀ , deliver more eﬀ ective treatment, and 
improve self-management, leading to improved patient 
outcomes.
This paper describes a trial of this approach in the 
example of depression. Depression aﬀ ects 3% of adults 
in the UK, is a chronic or relapsing disorder in about half 
of those aﬀ ected, accounts for about a quarter of primary 
care consultations, and has substantial adverse eﬀ ects on 
quality of life.5 There is evidence from systematic reviews 
in favour of telehealth interventions for depression, 
including those delivered by telephone6 or the 
internet.7–10 However, more than half of patients drop out 
of online therapy,9 and therapist support alongside 
internet-based interventions increases eﬀ ectiveness and 
improves retention of participants.7,9,10
Through a programme of research, including literature 
reviews,11 qualitative research,12 and a survey of patient 
views,13 we developed an evidence-based conceptual 
model for eﬀ ective use of telehealth to improve 
management of chronic disorders—the TElehealth in 
CHronic disease (TECH) model (appendix p 1).14 
Building on the Chronic Care Model,15 the TECH model 
Research in context
Evidence before this study
There is much scientiﬁ c literature about speciﬁ c telehealth 
interventions for diﬀ erent chronic disorders. Before developing 
the Healthlines intervention, we did a meta-review of existing 
systematic reviews. We searched MEDLINE, Embase/AMED, 
PsycInfo, Web of Science, Database of Abstracts of Reviews of 
Eﬀ ects (DARE), and The Cochrane Library between Jan 1, 2005, 
and March 31, 2010, for relevant systematic reviews. We used 
combinations of search terms for systematic reviews, telehealth, 
or telemedicine and a list of important chronic disorders 
(appendix p 13). We concluded that, although many studies had 
been done, many of these were of poor quality, with small 
sample sizes, methodological limitations, short-term follow-up, 
and insuﬃ  cient theoretical basis for interventions. This 
conclusion was supported by a more recent evidence synthesis 
that showed evidence of publication bias and concluded that the 
evidence base for telehealth for chronic disorders is “on the 
whole weak and contradictory”. We supplemented these reviews 
with a meta-review of existing systematic reviews of telehealth 
for depression, focusing on which technologies seemed to work 
best for which groups of patients. These reviews provided 
support for telephone-based and computerised-interventions 
for depression, especially internet interventions based on 
cognitive behavioural therapy (CBT), although limitations and 
inconsistencies in the evidence base were again notable. 
Some evidence suggested that professional support could 
improve the eﬀ ectiveness of computerised CBT. More recent 
reviews reinforce these conclusions. Although there is much 
policy enthusiasm for telehealth programmes, few large 
pragmatic trials of such programmes have been done with 
real-world implementation and a broad range of patients.
Added value of this study
Our trial builds on previous evidence by testing a new model of 
care that combines the use of various telehealth tools supported 
by non-clinically trained staﬀ . Our study provides robust support 
for the potential role of an integrated telehealth approach to 
support patients with depression in primary care. Our results 
showed that the Healthlines Depression Service increased the 
proportion of patients achieving a treatment response and also 
led to improvements in anxiety, self-management, patient 
satisfaction, and access to health care.
Implications of all the available evidence
Telehealth interventions for chronic disease can lead to small 
but meaningful improvements for patients. Basing the 
intervention design on a coherent conceptual model and 
including multiple evidence-based approaches in combination 
is likely to enhance eﬀ ectiveness. The promising ﬁ ndings from 
this study justify developing similar interventions for other 
chronic disorders.
See Online for appendix
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proposes that telehealth programmes need to address 
engagement of patients and health providers, promotion 
of self-management behaviours, optimisation of treat-
ment, and care coordination, and they need to be 
provided in partnership with usual primary care 
providers. We used the TECH model to design and 
assess telehealth interventions (The Healthlines Service) 
for two exemplar common chronic disorders: depression 
and raised cardiovascular risk. In this trial, we aimed to 
assess the eﬀ ectiveness of the Healthlines Service plus 
usual care compared with usual care alone for patients 
with depression in a large-scale, real-world application.
Methods
Study design and participants
This study was a pragmatic, multicentre, randomised 
controlled trial. Participants were recruited in three areas 
of England (around Bristol, Sheﬃ  eld, or Southampton). 
The trial was approved by the National Research Ethics 
Service Committee South West–Frenchay (Reference 
12/SW/0009). The study protocol has been reported 
previously.16 Readers interested in obtaining further 
information about the intervention materials should 
refer to the study website.
Participants were recruited from 43 general practices, 
which covered populations with various sociodemo-
graphic characteristics. Inclusion criteria were a score 
on the Patient Health Questionnaire 9 (PHQ-9)17 of at 
least 10 points and a conﬁ rmed diagnosis of depression 
on the Clinical Interview Schedule-Revised (CIS-R) 
scale,18 being aged 18 years or older, and having access 
to a telephone, the internet, and email. Participants 
were excluded if they were currently receiving therapy 
or case management from a mental health worker; had 
given birth in the previous 12 months; had a history of 
major bipolar disorder, psychotic illness, dementia, 
severe learning disability, or substance dependency; 
were receiving palliative care; had a signiﬁ cant suicide 
risk; or were unable to communicate verbally in 
English. Potentially eligible participants were also 
excluded if their general practitioner (GP) deemed that 
participation would cause distress (eg, because of a 
recent bereavement).
Potentially eligible participants were identiﬁ ed via 
searches of computerised general practice records for 
patients who had consulted a doctor for depression or 
low mood, or who had been prescribed antidepressants 
within the previous 2 months. We asked GPs to screen 
the list to remove patients with known exclusion criteria. 
A random sample of potentially eligible patients in each 
practice were sent postal information about the study 
and a PHQ-9 questionnaire. Patients who expressed an 
interest in the study and had a PHQ-9 score of at least 
10 were screened by researchers over the telephone to 
conﬁ rm eligibility, including use of the CIS-R to conﬁ rm 
a diagnosis of depression. Eligible patients were asked 
to complete a baseline questionnaire and consent form, 
either online or by post. If respondents indicated 
suicidal ideas during assessment of eligibility we asked 
their GP to assess whether they should be excluded 
from the trial.
Randomisation and masking
Participants who consented to participate were 
individually randomly allocated (1:1) to either the 
intervention plus usual care group or the usual care 
alone group. Allocation was done with an automated web 
randomisation system developed independently by the 
Bristol Randomised Controlled Trials Collaboration 
(Bristol, UK). Randomisation was stratiﬁ ed by location 
(Bristol, Sheﬃ  eld, or Southampton) and minimised by 
general practice and baseline PHQ-9 depression score 
(10–14, 15–19, ≥20). Participants were notiﬁ ed of their 
allocation by email. Participants were aware of their 
assignment to the intervention or control groups. 
Outcome data were collected by participant self-report or 
electronic download from general practice computer 
records, and the trial statisticians analysed the outcomes 
masked to allocation.
Procedures
This was a complex intervention incorporating use of 
technologies supported by non-clinically trained staﬀ  to 
address each of the components of the TECH model. 
To apply the model to a speciﬁ c clinical disorder, we 
sought to identify telehealth tools that had some evidence 
of eﬀ ectiveness in that disorder and that could be used to 
implement the strategies within the TECH model. 
Therefore the speciﬁ c telehealth tools varied for the 
diﬀ erent exemplar disorders, but were delivered by the 
Healthlines Service within a common intervention 
framework (shown for depression in the appendix [p 2]).
The intervention was originally provided by staﬀ  from 
NHS Direct, which, until March 2014, provided various 
telehealth services through a national network of call 
centres and a website. After NHS Direct closed in March, 
2014, the Healthlines Service was transferred to Solent 
NHS Trust. The Healthlines Service was based on regular 
telephone calls from a health adviser who was supported 
by interactive software. The advisers were not clinically 
qualiﬁ ed but had experience working for NHS Direct 
and had a further 3 weeks of training in health 
coaching, motivational interviewing, antidepressant drug 
treatment, use of a computerised cognitive behavioural 
therapy (CBT) programme, and the Healthlines 
telephone support software. With the help of scripts 
generated by the interactive software, the advisers 
supported participants in addressing their own health 
goals and directed them to relevant online resources, 
including reliable health information, interactive pro-
grammes, and relevant apps and widgets (eg, to help 
with increasing exercise). The advisers emailed links to 
appropriate websites to participants or sent them the 
information by post.
For the study website see 
http://www.bristol.ac.uk/
healthlines/
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Participants were given access to a Healthlines web 
portal, which linked to several resources, including the 
Living Life to the Full Interactive (LLTTFi) programme. 
This interactive multimedia programme delivers 
computerised CBT-based treatment for depression 
through six self-directed sessions, to be completed 
roughly every two weeks.19 Alternatively, participants 
could choose to follow similar material in book form.20 
The web portal also provided information about 
depression, links to relevant patient-led organisations 
and a link to Big White Wall, which is a digital mental 
health network that includes a clinically moderated 
online forum.
After an initial assessment and goal-setting telephone 
call, the advisers called each participant on six occasions 
roughly equally spaced over 4 months, and then made 
up to three more calls at roughly two month intervals to 
provide reinforcement and to detect relapse. As well as 
providing support in use of the CBT programme (online 
or in book form), the telephone scripts included modules 
covering the monitoring of depression symptoms, drug 
treatment, medication adherence, exercise, and alcohol 
use. To ensure coordination with primary care, the 
advisers sent regular progress reports to participants’ 
GPs by email and copied them to participants via the 
Healthlines portal. In cases of inadequate treatment 
response, the advisers contacted participants’ GPs to 
recommend escalation of medication, enclosing a 
summary of current treatment guidelines.5 This 
approach was based on our aim to support, rather than 
to undermine, the work of the participants’ main 
primary care providers. Each participant was telephoned 
by the same adviser on each occasion when possible, 
since we had identiﬁ ed that it was important to avoid an 
anonymous call-centre approach to promote participant 
engagement.11 Photographs of the advisers were provided 
on the Healthlines web portal to enhance the sense of 
personal care. To facilitate access to care, the Healthlines 
Service was available from 1000 h to 2000 h on weekdays 
and from 1000 h to 1400 h on Saturdays.
NHS Direct was closed down towards the end of the 
trial, therefore delivery of the intervention was paused 
for 2 months while it was transferred to Solent NHS 
Trust. Two-ﬁ fths of participants had a gap in service 
provision during this transfer and some did not receive 
the full number of intended phone calls before the end of 
their 12 month follow-up period.
Outcomes
The primary outcome was the proportion of participants 
responding to the intervention, deﬁ ned as a PHQ-917 
score of less than 10 and a reduction in PHQ-9 of at least 
5 points, 4 months after randomisation. Secondary 
outcomes were PHQ-9 as a binary outcome at 8 and 
12 months and as a continuous outcome at 4, 8, and 
12 months; anxiety (GAD-7);21 quality of life (EQ-5D-5L);22 
satisfaction with treatment received and with amount of 
support received (patient satisfaction); perceived access to 
care; self-management skills and self-eﬃ  cacy (HeiQ);23 
use of telehealth interventions; medication adherence 
(Morisky);24 health literacy (eHEALs);25 and perceptions of 
care coordination (Haggerty).26 We pre-speciﬁ ed questions 
about internet use and experience but did not analyse 
these questions in order to reduce the number of 
secondary outcomes. These secondary outcomes were 
For the Big White Wall see 
http://www.bigwhitewall.com
Figure 1: Trial proﬁ le 
Primary outcome incomplete indicates patients who did not answer enough questions in their Patient Health 
Questionnaire-9 to allow calculation of a valid score.
609 randomly assigned
609 enrolled
2375 assessed for eligibility
16 570 patients invited
1766 excluded
1649 did not meet inclusion criteria
967 PHQ-9 score <10
438 no CIS-R depression diagnosis
67 no internet or email
177 any other reason
25 declined to participate
92 other
14 195 excluded
9555 no response
4400 declined to participate
240 other
307 assigned to intervention plus usual care
307 received intervention
86 received in full (9 or 10 calls)
131 received in part (3 to 8 calls)
78 received little or none (2 calls or fewer)
12 missing data
255 assessed at 4 months
52 excluded from analysis
1 primary outcome incomplete
27 withdrawn from study
24 lost to follow-up
252 assessed at 8 months
61 excluded from analysis
1 primary outcome incomplete
33 withdrawn from study
27 lost to follow-up
255 assessed at 12 months
52 excluded from analysis
36 withdrawn from study
16 lost to follow-up
270 assessed at 4 months
32 excluded from analysis
2 primary outcome incomplete
9 withdrawn from study
21 lost to follow-up
263 assessed at 8 months
39 excluded from analysis
17 withdrawn from study
22 lost to follow-up
261 assessed at 12 months
41 excluded from analysis
19 withdrawn from study
20 lost to follow-up
2 died
302 assigned to usual care alone
301 received usual care
1 did not receive allocated usual care
1 received part of intervention due to
administrative error
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chosen to assess the eﬀ ect of the intervention on the 
various components of the underlying TECH model. 
At baseline, we also obtained details of socio-demographic 
characteristics and current treatment for depression. All 
measures were collected through patient questionnaires, 
completed online or by post, at baseline and at 4, 8, and 
12 months after randomisation. We attempted to follow up 
non-respondents by email, telephone, and post. 
Participants were oﬀ ered the option of completing just 
the primary outcome during their second reminder, 
which could have been by post, email or phone. After 
12 months, we collected data from computerised general 
practice records about consultations and prescriptions for 
antidepressants. We obtained data about use of the 
intervention from Healthlines Service records. All 
potential serious adverse events were investigated. 
Adverse events were mainly detected as part of the 
collection of data with respect to resource use during the 
12 month follow-up period, either collected within 
the patient questionnaires or during the review of 
participants’ medical records in primary care at the end of 
the trial. We collected data about any hospital attendance 
or new or recurrent serious medical events recorded in 
primary care records during the 12 month period.
Statistical analysis
We chose the sample size pragmatically, taking into 
account the size of eﬀ ect that would be likely to aﬀ ect 
practice and that might be feasible. Assuming a 30% 
response to treatment in the control group and 20% 
attrition, 300 participants in each group would provide 
80% power (α of 5%) to detect a diﬀ erence of 13% and 
90% power (α of 1% ) to detect a diﬀ erence of 18%.
We used descriptive statistics to compare baseline 
characteristics of trial participants by allocated group. 
If we detected important imbalances between the 
intervention and control groups, these variables were 
included in regression models in sensitivity analyses of 
the primary outcome. We ﬁ tted all regression models 
with maximum likelihood estimation, apart from the 
regression models that used multiply imputed data, for 
which we used QR decomposition.
We did the primary analysis with a mixed-eﬀ ects logistic 
regression model adjusted by the stratiﬁ cation and 
minimisation variables of site (categorical), baseline value 
of the outcome (continuous), and general practice 
(categorical, included as a random eﬀ ect). In the primary 
analysis, we included all participants with complete data in 
accordance with their allocated treatment, based on the 
principle of intention to treat without imputation. We 
investigated the robustness of the primary analysis to 
diﬀ erent methods of imputing missing outcome data: 
simple imputation that assumed no treatment response or 
multiple imputation (appendix p 5).27 We also investigated 
the eﬀ ect of omitting GP practice as a random eﬀ ect, and 
adjusting for time between randomisation and follow-up 
and variables imbalanced between the groups at baseline.
By ﬁ tting interaction terms between trial groups and 
subgroup variables, we investigated whether any eﬀ ect of 
the Healthlines intervention diﬀ ered by subgroups 
deﬁ ned at baseline by sex, age, PHQ-9 score, severity of 
depression, or use of antidepressant medication.
Usual care alone 
(n=302)*
Intervention plus usual 
care (n=307)*
Demographic
Age (years) 50·0 (12·8)† 49·1 (12·9)‡
Female 204/302 (68%) 213/307 (69%)
White 292/301 (97%) 300/306 (98%)
Employment situation
Full-time employment 92/299 (31%) 88/303 (29%)
Part-time employment 39/299 (13%) 56/303 (18%)
Full-time education 2/299 (1%) 5/303 (2%)
Unemployed 13/299 (4%) 14/303 (5%)
Unable to work due to long-term illness/disability 78/299 (26%) 73/303 (24%)
Unable to work due to carer responsibilities 2/299 (1%) 4/303 (1%)
Fully retired from work 44/299 (15%) 40/303 (13%)
Looking after the home 10/299 (3%) 13/303 (4%)
Doing something else 19/299 (6%) 10/303 (3%)
Occupation (most recent or current)
Administrative or secretarial occupations 51/262 (19%) 49/270 (18%)
Associate professional or technical occupations 37/262 (14%) 35/270 (13%)
Elementary occupations 21/262 (08%) 19/270 (7%)
Managers or senior oﬃ  cials 32/262 (12%) 41/270 (15%)
Personal services 28/262 (11%) 27/270 (1%)
Process, plant, and machine operatives 11/262 (4%) 15/270 (6%)
Professionals 35/262 (13%) 42/270 (16%)
Sales and customer services 35/262 (13%) 29/270 (11%)
Skilled trades 12/262 (5%) 13/270 (5%)
Highest education qualiﬁ cation achieved
Degree or higher degree 84/298 (28%) 68/303 (22%)
A levels or equivalent 54/298 (18%) 63/303 (21%)
GCSEs/O levels or equivalent 119/298 (40%) 130/303 (43%)
No qualiﬁ cations 41/298 (14%) 42/303 (14%)
Accommodation
Own accommodation or buying with mortgage 162/300 (54%) 179/307 (58%)
Part-rent or rent accommodation 124/300 (41%) 118/307 (38%)
Live rent free 14/300 (5%) 10/307 (3%)
Index of multiple deprivation 18·0 (13·0)§ 18·3 (12·8)‡
Clinical data
Previously treated for depression 258/276 (93%) 269/295 (91%)
PHQ-9 score 16·7 (4·7)† 17·1 (4·5)‡
GAD-7 score 12·4 (5·0)¶ 13·5 (4·6)||
Categorised with mild depression from CIS-R 52/302 (17%) 39/307 (13%)
Categorised with moderate depression from CIS-R 148/302 (49%) 165/307 (54%)
Categorised with severe depression from CIS-R 102/302 (34%) 103/307 (34%)
Taking antidepressants 258/288 (90%) 251/289 (87%)
Data are n/N (%) or mean (SD). GCSE=General Certiﬁ cate of Secondary Education. PHQ-9=Patient Health 
Questionnaire 9. GAD-7=Generalised Anxiety Disorder scale. CIS-R=Clinical Interview Schedule-Revised scale. 
*Denominators vary because of missing data. †n=302. ‡n=307. §n=301. ¶n=298. ||n=304.
Table 1: Baseline characteristics
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To estimate the eﬀ ect of the Healthlines intervention at 
12 months when received as intended, we described 
compliance as little or none (two telephone calls or fewer), 
partial (three to eight calls), or full (nine or ten calls). We 
estimated the complier-average causal eﬀ ect (CACE) with 
principal stratiﬁ cation in two ways, classifying partial 
compliers as either non-compliers or full compliers.
We did repeated measures analyses of the primary 
outcome, as both a binary and continuous outcome, 
using appropriate mixed-eﬀ ect regression models, 
including general practice as a random eﬀ ect, 
participants as random intercepts, and assuming an 
independent covariance structure. We investigated 
whether the between-group diﬀ erence changed over 
time by ﬁ tting an interaction between trial group and 
follow-up timepoint. In the absence of any such 
interactions, we report the average between-group eﬀ ect 
across 12 months.
Secondary outcomes were analysed in a similar manner 
to the primary analysis. We estimated between-group 
eﬀ ects with linear, logistic, or binomial mixed-eﬀ ect 
regression models, adjusted for stratiﬁ cation and 
minimisation variables and continuous value of the 
outcome at baseline (if appropriate). Participants were 
analysed as randomised, without imputation of missing 
data. We did no sensitivity analyses for secondary 
outcomes. To reduce the number of statistical comparisons, 
we estimated between-group diﬀ erences for secondary 
outcomes only at the 12 month follow-up timepoint. We 
described serious adverse events by study group.
We did analyses using Stata version 13.1. The trial 
was overseen by an Independent Trial Steering 
Committee and an Independent Data Monitoring 
Committee, who agreed a statistical analysis plan 
before analysis. Two patient and public representatives 
actively contributed as members of the Trial Steering 
Committee. The trial is registered with Current 
Controlled Trials, number ISRCTN 14172341.
Role of the funding source
The funder of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had 
full access to all the data in the study and had 
ﬁ nal responsibility for the decision to submit for 
publication.
Results
Participants were recruited and randomly assigned to 
study groups between July 24, 2012, and July 31, 2013. 
Of 2375 participants assessed for eligibility,  1649 (69%) did 
not meet eligibility criteria, mainly because they did not 
meet the diagnostic criteria for depression (1405 [85%] of 
1649 patients not meeting the eligibility criteria). Of the 
726 eligible participants, 609 participants were randomly 
assigned, with 307 assigned to intervention plus usual care 
and 302 assigned to usual care alone (ﬁ gure 1). Primary 
outcome data were obtained for 255 (83%) participants in 
the intervention group and 270 (89%) in the usual care 
group. We retained 516 (85%) participants until the ﬁ nal 
12 month follow-up assessment.
Table 1 shows baseline characteristics of participants 
who entered randomisation. Most participants had 
severe and enduring depression. Of patients with data 
available, 205 (34%) were classiﬁ ed as severely depressed 
at baseline, 527 (92%) had previously been treated for 
depression, and 509 (88%) were currently taking 
antidepressant medication. The intervention and 
control groups were mostly well balanced, although 
there were small diﬀ erences in work status, education, 
accommodation, depression severity, and use of 
antidepressants.
Analysis of the primary outcome showed that 68 (27%) 
of 255 participants in the intervention group responded 
to treatment at 4 months, compared with 50 (19%) of 
270 participants in the control group (adjusted odds ratio 
[OR] 1·7, 95% CI 1·1–2·5, p=0·019; table 2). This 8% 
diﬀ erence between groups in the proportion of 
participants responding to treatment is equivalent to a 
number needed to treat of 12. This result was robust to 
sensitivity analyses (appendix p 6). No evidence suggested 
that the intervention was diﬀ erentially eﬀ ective for any 
subgroups deﬁ ned by baseline characteristics.
The proportion of participants who responded to 
treatment increased in both arms at 8 and 12 months 
(table 2). Although the between-group diﬀ erence seemed 
to diminish with increasing duration of follow-up, there 
was no evidence of an interaction between treatment 
group and timepoint (pinteraction=0·402). Therefore, we 
estimated an overall treatment eﬀ ect from all follow-up 
data at 4, 8, and 12 months in two repeated measures 
analyses, binary and continuous. This suggested a positive 
average eﬀ ect of the intervention over the 12 month 
follow-up period (binary response to treatment p=0·035). 
Mean PHQ-9 scores also decreased over time for both 
groups (table 3), with no evidence of an interaction 
between treatment group and timepoint (pinteraction=0·345). 
A repeated measures analysis of continuous PHQ-9 
scores provided evidence of a small overall treatment 
eﬀ ect (p=0·045).
Usual care Intervention plus 
usual care
Adjusted odds ratio 
(95% CI)
p value
4 months 50/270 (19%) 68/255 (27%) 1·7 (1·1–2·5) 0·019
8 months 61/263 (23%) 75/252 (30%) 1·4 (1·0–2·2) NC
12 months 86/261 (33%) 95/255 (37%) 1·2 (0·9–1·8) NC
Average of 4, 8, and 
12 month eﬀ ects*
·· ·· 1·6 (1·0–2·6) 0·035
Data are n/N (%) unless otherwise stated. All analyses are adjusted by site (Bristol, Sheﬃ  eld, or Southampton) and 
baseline PHQ-9 score. GP practice is included as a random eﬀ ect. NC=not calculated at individual timepoints; analysis 
plan speciﬁ ed repeated measures analysis. *Based on a repeated measures analysis that was additionally adjusted by 
follow-up timepoint as a categorical variable. 
Table 2: Repeated measures analysis of treatment response as a binary outcome
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Table 3 shows the ﬁ ndings for the secondary outcomes, 
except for use of telehealth interventions, which is shown in 
the appendix (p 7). The intervention was associated with 
improvements in anxiety, as assessed with the GAD-7 
instrument.21 It was also associated with improvements in 
several measures of self-management skills and attitudes 
and improved health literacy.25 Participants in the 
intervention group expressed greater satisfaction with 
access to health care, treatment, and amount of support 
they received. There was no evidence of improved adherence 
with antidepressant medication or improved care 
coordination (table 3) or that participants made more use of 
other health-related technologies (appendix p 7). For ease of 
presentation, table 3 only shows data about secondary 
outcomes after 12 months’ follow-up. Details of ﬁ ndings 
after 4 and 8 months are available in the appendix (p 8).
Use of the intervention varied considerably, with some 
participants dropping out after a few calls while others 
completed the complete course of telephone calls. 
Figure 2 shows the number of Healthlines encounters 
with intervention participants out of a maximum of 
ten encounters. The median number of encounters was 
ﬁ ve (IQR 2–9, 295 participants had available data), mean 
encounter duration was 18·5 min (SD 12·7), and there 
was a total of 1972 encounter calls.
Usual care Intervention plus usual care Adjusted diﬀ erence in 
means (95% CI)
p value
Patients with 
data available
Unadjusted 
mean (SD)
Patients with 
data available
Unadjusted mean 
(SD)
PHQ-9 score (continuous outcome)
Baseline 302 16·7 (4·7) 307 17·1 (4·5) ·· NA
4 months 270 13·8 (6·2) 255 13·3 (6·1) –0·8 (–1·8 to 0·1) NC
8 months 263 13·4 (6·2) 252 12·4 (6·2) –1·2 (–2·2 to –0·3) NC
12 months 261 11·9 (6·4) 255 11·6 (6·2) –0·5 (–1·5 to 0·5) NC
Average of 4, 8, and 12 month eﬀ ects* ·· ·· ·· ·· –0·8 (–1·6 to 0·0) 0·045
Generalised anxiety (GAD-7)21 237 9·2 (5·8) 223 8·7 (5·5) –1·1 (–2·0 to –0·2) 0·019
Quality of life (EQ-5D-5L)22 227 0·564 (0·30) 219 0·569 (0·30) –0·003 (–0·04 to 0·04) 0·896
Satisfaction with treatment†‡ 184 3·3 (0·9) 193 3·7 (0·9) 0·5 (0·3 to 0·6) <0·001
Diﬃ  culties with obtaining access to care†‡ 232 4·2 (1·9) 216 4·5 (1·9) 0·3 (0·0 to 0·6) 0·038
Satisfaction with amount of support received†‡ 177 2·1 (0·9) 185 2·6 (0·8) 0·6 (0·4 to 0·7) <0·001
Self-management skills and self-eﬃ  cacy (heiQ)23 235 2·4 (0·9) 221 2·5 (0·9) ··
Physical activity† (heiQ health-directed behaviour scale) 237 2·4 (0·9) 221 3·0 (0·5) 0·1 (<0·0 to 0·2) 0·118
Self-monitoring and insight† 238 2·6 (0·6) 221 2·7 (0·6) 0·1 (0·0 to 0·2) 0·005
Constructive attitudes and approaches† 239 2·6 (0·5) 221 2·8 (0·5) 0·0 (–0·1 to 0·1) 0·480
Skill and technique acquisition† 238 2·8 (0·6) 220 2·9 (0·6) 0·2 (0·1 to 0·2) 0·001
Health services navigation† 179 3·4 (0·9) 173 3·2 (1·1) 0·2 (0·1 to 0·3) <0·001
Adherence to antidepressant medication (Morisky)24† 235 3·7 (0·8) 220 3·9 (0·8) –0·1 (–0·2 to 0·1) 0·511
Health literacy (eHEALs)25† ·· ·· 174 ·· 0·2 (0·1 to 0·4) <0·001
Care coordination (Haggerty)26 176 3·1 (2·2) 179 3·5 (2·4) ··
Role clarity and coordination† 236 3·1 (1·0) 219 3·2 (1·0) –0·1 (–0·2 to 0·1) 0·361
Evidence of a care plan† 230 3·2 (1·2) 210 3·1 (1·2) 0·3 (–0·1 to 0·8) 0·173
Overall experience of organisation of health care† ·· ·· ·· ·· 0·1 (–0·1 to 0·3) 0·247
Self-organisation of health care† ·· ·· ·· ·· 0·0 (–0·2 to 0·2) 0·841
All analyses are adjusted by site (Bristol, Sheﬃ  eld or Southampton), baseline outcome (if measured) and baseline PHQ-9 score. GP practice is included as a random eﬀ ect. PHQ=patient health questionnaire. 
HeiQ=Health Education Impact Questionnaire. NC=not calculated at individual timepoints; analysis plan speciﬁ ed repeated measures analysis. NA=not applicable. *Based on a repeated measures analysis that was 
additionally adjusted by follow-up timepoint as a categorical variable. †Higher score is more positive (fewer access diﬃ  culties, greater satisfaction). ‡Based on scales generated before the main trial analysis using 
principal components analysis and incorporating questions taken from existing validated questionnaires or constructed for this research.
Table 3: Secondary outcomes and measures used to assess them
Figure 2: Distribution of Healthlines telephone encounters from 295 patients
Data about use of the intervention were missing for 12 participants who received 
the intervention.
0 10987654321
60
65
55
50
45
40
35
30
25
20
15
10
5
0
N
um
be
r o
f p
ar
tic
ip
an
ts
 w
ith
 d
ep
re
ss
io
n
Number of encounters
Articles
522 www.thelancet.com/psychiatry   Vol 3   June 2016
Only 86 (28%) of 307 of participants in the intervention 
group received at least nine of the potential maximum 
of ten telephone encounters. Table 4 shows the crude 
estimated eﬀ ect at 12 months among compliers, after 
classifying partial compliers in the intervention group as 
either non-compliers or full compliers. The results 
suggest an increase in eﬀ ect when compliance is deﬁ ned 
as completion of most or all of the Healthlines encounters.
Use of diﬀ erent components of the intervention also 
varied. Generally, sustained usage was low, although 
some individuals used the resources extensively. Out of 
285 participants in the intervention group with valid data, 
237 chose to use the online computerised CBT programme 
(LLTFi) and 53 chose to follow the book (eight individuals 
used both). Of those choosing LLTFi, 204 participants 
logged on to the website and completed a median of two 
(IQR 0–5) of the seven modules. 66 participants who 
logged on did not complete the ﬁ rst module. 
98 participants registered with Big White Wall and logged 
on to the website at least once. The median number of 
logins was two (range 1–104), the median number of 
interactions (posts) was zero (range 0–49), and the time 
spent on the site was 0·30 h (range 0·00–11·17).
In a prespeciﬁ ed exploratory analysis of the process of 
care, participants in the intervention group had slightly 
more primary care consultations during 12 months 
(mean 15·4, SD 11·0) than did those in the control group 
(mean 14·3, SD 12·5; adjusted incidence ratio 1·07, 
95% CI 0·96–1·19, p=0·22). There were no diﬀ erences 
between the intervention and control groups in the 
proportion of participants who had been prescribed an 
antidepressant during the trial, the number of changes 
in antidepressant type or dose, or the number of 
participants who were taking an antidepressant at 
follow-up (appendix p 11).
During the course of the trial, 70 adverse events were 
reported by participants (36 in the usual care group and 
34 in the intervention group), of which one was related 
to the intervention (increased anxiety from talking 
about depression) and was not serious (appendix p 12). 
Two patients died (one due to COPD and one due to 
throat cancer), both in the usual care group.
Discussion
This report describes a large pragmatic trial of the 
Healthlines depression service, a novel approach to the 
delivery of health care through a combination of various 
technologies to improve treatment and self-management, 
supported by lay staﬀ , and integrated with the health-care 
system. The intervention was clinically eﬀ ective, leading 
to improved response to treatment at 4 months’ for 
participants receiving the intervention plus usual care 
compared with those receiving usual care alone, and the 
size of the eﬀ ect is important, with a number needed to 
treat of 12. Furthermore, compared with participants 
who received usual care alone, participants who received 
the intervention reported reduced anxiety, improved 
access to health support and advice, greater satisfaction 
with the treatment and the amount of help they 
received, and improvements in self-management 
attitudes and skills.
The eﬀ ect of the intervention was greatest after 
4 months of follow-up, and the diﬀ erence between the 
intervention and usual care groups narrowed with time 
as both groups improved. After 12 months of follow-up, 
evidence suggested no beneﬁ t from the intervention, 
although an average beneﬁ t existed for the whole 
12 month follow-up period. Therefore, the main eﬀ ect of 
the intervention in terms of depression was increased 
speed of recovery, which is nevertheless important. 
However, only a few participants fulﬁ lled our criteria for 
response to treatment, whether they received the 
intervention or usual care, and the mean PHQ-9 score 
was more than 10 in both groups at all timepoints, 
suggesting substantial residual symptoms. Notably, 
many participants had severe and enduring depression 
when they were recruited to the trial, most were taking 
antidepressants, and most remained symptomatic at the 
end of the trial. These results suggest that many 
participants had so-called treatment-resistant depression, 
which is unsurprising, since this pattern of a long history 
of depression and poor treatment response is typical 
of patients managed in primary care. More than 
three-quarters of patients treated with antidepressants in 
primary care for at least 6 weeks have clinically signiﬁ cant 
PHQ-9 response at 12-month follow-up Partial compliers 
classiﬁ ed as 
non-compliers
Partial compliers 
classiﬁ ed as full 
compliers
Usual care Intervention plus 
usual care
No intervention received (0–2 encounters started) 86/261 (33%) 16/52 (31%) ·· ··
Partial intervention received (3–8 encounters started) ·· 42/111 (38%) ·· ··
Full intervention received (9–10 encounters started) ·· 36/86 (42%) 1·9 (0·99–3·48) 1·3 (0·87–1·95)
Data are n/N (%) or unadjusted odds ratio (95% CI). We estimated the eﬀ ect among compliers at 12 months because this was the scheduled duration to receive the entire 
intervention. Three participants who never received the Healthlines intervention and one participant who only received an unscheduled non-encounter call are categorised as 
receiving none of the intervention. 12 participants had missing encounter data.
Table 4: Complier-average causal eﬀ ect analysis at 12 months
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residual symptoms because of complex reasons such as 
insuﬃ  cient eﬀ ect of or intolerance to medication, non-
adherence, and under treatment.28 This evidence is 
consistent with the notion that depression is often a 
chronic disease and shows the challenge of improving 
care for patients with treatment-resistant depression.
Management options for treatment-resistant depression 
include changes of medication, increased dosage, 
addressing of non-adherence, or addition of psychological 
therapy. This Healthlines intervention was designed to 
address all of these issues, for example through strategies 
to promote adherence, oﬀ ering computerised CBT, and 
sending guidance to GPs about changes to medication. 
Our data suggest that the proposed mechanisms of action 
were only partly achieved, with no evidence of improved 
medication adherence or that GPs were more active in 
changing medication. Many participants only used some 
components of the intervention to a small extent, and only 
a few received the full course of telephone consultations 
that formed the core of the intervention. However, some 
participants engaged with the intervention extensively, 
and our analysis suggested that adherence to the 
intervention was associated with enhanced eﬀ ectiveness.
Therefore, it is likely that the main mechanisms of 
eﬀ ect were the support and motivation received from 
the Healthlines advisers to improve self-management, 
along with the addition of computerised CBT to 
existing drug treatment. To improve eﬀ ectiveness of 
the intervention, exploration of ways to improve 
communication with primary care will be necessary to 
improve medication optimisation. Such exploration 
might be easier outside of a research context once 
the intervention is well established and has been 
normalised within the health-care system. To improve 
patient engagement, prescreening might be beneﬁ cial 
to target the intervention at those who would be most 
interested in using this approach.
Findings from systematic reviews6–10 have suggested 
positive eﬀ ects on patient outcomes from various 
speciﬁ c telehealth interventions for depression, 
although some investigators have pointed out 
methodological limitations in the evidence base, 
including the abundance of small feasibility studies, 
assessment of a small range of outcomes, and only 
short-term follow-up. Another systematic review8 
described the evidence for internet-supported treatment 
for depression as promising but inconclusive. Several 
trials of computerised CBT for depression have had 
positive results, but these have had limitations and a 
high quality trial of two computerised CBT packages 
with regular telephone support showed no evidence of 
beneﬁ t from either package compared with usual GP 
care.29 Very few pragmatic trials have been done to study 
system-level telehealth interventions for depression that 
integrate various technologies and new ways of working 
implemented by non-clinically trained staﬀ . Our study 
helps to ﬁ ll this evidence gap.
The most similar previous study, which was done in 
the USA, was based on a so-called collaborative care 
model. Care managers were provided with a web-based 
clinical decision-support system, but the intervention did 
not make use of any other telehealth approaches.30 
The adjusted odds ratio for treatment response was 
1·9 (95% CI 1·09–3·45) at 6 months follow-up, similar to 
the estimate of treatment response at 4 months in this 
UK-based Healthlines trial (1·7, 95% CI 1·1–2·5). Several 
studies of other collaborative care interventions have 
been done that often involve telephone follow-up from 
case managers, but have not included the integrated use 
of internet or other telehealth resources, which is a 
deﬁ ning characteristic of the Healthlines intervention. 
A Cochrane review31 estimated that the risk ratio for 
response from collaborative care for depression was 
1·32 (95% CI 1·22–1·43) in the short term (0–6 months) 
and 1·31 (95% CI 1·17–1·48) in the medium term 
(6–12 months). The ﬁ ndings from our trial are similar to 
these results, but slightly more positive (the observed 
adjusted odds ratio at 4 months follow-up equates to a 
risk ratio of 1·5, 95% CI 1·1–1·9).
This trial has several strengths, including a large 
sample size, inclusion of participants with a conﬁ rmed 
diagnosis of depression, the high proportion of 
participants retained, and recruitment from multiple 
sites. The study is highly pragmatic, testing a new 
approach to care based on telehealth, which could be 
quickly and easily rolled out nationally. The intervention 
was carefully developed with an evidence-based 
conceptual model that helps us to explore causal 
mechanisms and provides a framework for development 
and evaluation. Alongside the trial, we did parallel 
process and economic assessments that will be reported 
separately.
The study also has several limitations. First, only a small 
proportion of those patients sent information about the 
trial expressed interest in participating. Targeting of the 
initial mailing to the population of patients meeting our 
severity criteria for depression was not possible. Therefore, 
we cannot establish how many of the individuals who did 
not respond to the invitation would not have been eligible 
because they did not have depression or would not meet 
severity criteria and how many were not interested in the 
intervention or did not wish to participate in this research 
study. Absence of interest or ability to use the intervention 
is not necessarily a threat to external validity, because we 
recognise that telehealth interventions are not necessarily 
suitable or of interest to everyone. However, if those 
responding to the invitation to participate in the research 
are unrepresentative, the ﬁ ndings might not be 
generalisable. If the intervention was implemented widely, 
it is possible that people with diﬀ erent characteristics or 
severity of depression would take it up, but whether the 
beneﬁ t would be greater or less than that we observed is 
impossible to know. This problem of low recruitment is 
common to other large trials of depression in primary 
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care, which have recruited patients by use of similar 
methods.28,32 In this trial, once eligibility had been 
conﬁ rmed, the proportion of eligible individuals who 
agreed to participate was high (84%).
Another limitation is the high proportion of participants 
who received less than a full course of encounters with 
the health adviser. This problem is also common in other 
telehealth interventions for depression.9 In this trial, the 
missed encounters might have occurred for various 
reasons; some individuals chose not to continue with the 
telephone calls (possibly because they got better), some 
became uncontactable, and others missed encounters 
because of the closure of NHS Direct. These ﬁ ndings 
might help to explain the positive beneﬁ t seen when 
response to treatment (based on the PHQ-9 score) was 
treated as a binary outcome, yet minimal change seen 
when the PHQ-9 score was treated as continuous. This 
result suggests that a proportion of individuals beneﬁ ted 
from the Healthlines service, but many people did not, 
which would be consistent with the ﬁ nding that one 
group of individuals dropped out of the service after just 
two or three encounters and another group completed 
the course and with the ﬁ nding that those who completed 
the course gained most beneﬁ t. A further limitation 
was that, although the overall retention was high, the 
retention rate diﬀ ered slightly between the intervention 
and usual care arms. However, multiple imputation of 
missing primary outcome data had no eﬀ ect on the 
ﬁ ndings, so we think that it is unlikely that diﬀ erential 
attrition could explain our results.
Our ﬁ ndings show that it is feasible and eﬀ ective to 
provide a scalable intervention for depression delivered by 
non-clinically trained advisers working with computerised 
algorithms and encouraging people to make use of the 
wide range of help available from the internet. Such an 
intervention makes it possible to substantially expand 
provision of care without being limited by the availability 
of clinically trained staﬀ , which would help to meet the 
pressing need to expand services for common mental 
health problems. Although the absolute beneﬁ t from this 
intervention in terms of clinical outcomes is small, the 
number of patients with the potential to beneﬁ t is very 
large and the results are suﬃ  ciently promising to justify 
further development of the intervention to improve its 
acceptability and eﬀ ectiveness. Further research should 
explore the beneﬁ ts of interventions based on a similar 
model for other chronic disorders.
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